Skip to main content
OpenTrials

Clinical trial condition

Gastroenteropancreatic Neuroendocrine Tumor

Explore clinical trials studying Gastroenteropancreatic Neuroendocrine Tumor. Study availability and eligibility vary by location and protocol.

20 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Gastroenteropancreatic Neuroendocrine Tumor trial results

Completed

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

NCT04727723

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumor, Neoplasms, +5 more
Locations
  • Novartis Investigative Site Alessandria, Italy
  • Novartis Investigative Site Bologna, Italy
  • Novartis Investigative Site Brescia, Italy
  • Novartis Investigative Site Cona, Italy
View all 18 locations
View Trial Details
Completed

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

NCT02611024

Conditions
Adenoma, Adnexal Diseases, Advanced Solid Tumors, +53 more
Locations
  • Sarcoma Oncology Center Santa Monica, California, United States
  • Massachusetts General Hospital - Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 23 locations
View Trial Details
Completed

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

NCT04986085

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumor, Neoplasms, +5 more
Locations
  • Hospital Universitario Virgen de la Arrixaca El Palmar, Murcia, Spain
  • Hospital Universitario Vall d´Hebron Barcelona, Spain
  • Hospital Universitario Reina Sofia Córdoba, Spain
  • Hospital Universitario de Cabueñes Gijón, Spain
View all 16 locations
View Trial Details
Completed

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

NCT03980925

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumor, Neoplasms, +6 more
Locations
  • Institut Català d'Oncologia Badalona Badalona, Barcelona, Spain
  • Institut Català d'Oncologia l'Hospitalet L'Hospitalet de Llobregat, Barcelona, Spain
  • Vall d'Hebron University Hospital Barcelona, Spain
  • Hospital Universitario 12 de Octubre Madrid, Spain
View Trial Details
Completed

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

NCT04852679

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumor
Locations
  • Cancer Hospital Chinese Academy of Sciences Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • The First Affiliated Hospital, Sun Yat-Sen University Guangzhou, Guangdong, China
View all 14 locations
View Trial Details
Completed

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

NCT03017690

Conditions
Gastro-enteropancreatic neuroendocrine tumor, Gastroenteropancreatic Neuroendocrine Tumor
Locations
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • Ochsner Medical Center Kenner Kenner, Louisiana, United States
  • Mercy Medical Center Baltimore, Maryland, United States
  • National Translational Research Group East Setauket, New York, United States
View Trial Details
Active, Not Recruiting

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

NCT06790706

Conditions
Adenocarcinoma, Anaplastic Thyroid Carcinomas, Carcinoid Tumor, +27 more
Locations
  • Institut de Cancerologie de l'Ouest , medical oncology department Angers, France
  • Institut Bergonié, medical oncology department Bordeaux, France
  • Hospices Civils de Lyon, Thoracic Oncology Department, Louis Pradel Hospital Bron, France
  • Centre Hospitalier Universitaire de Lille, medical oncology department Lille, France
View all 15 locations
View Trial Details
Active, Not Recruiting

Neuroendocrine Tumors - Patient Reported Outcomes

NCT05064150

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Neuroendocrine, +11 more
Locations
  • University of Florida Gainesville, Florida, United States
  • University of Iowa Iowa City, Iowa, United States
  • University of Kansas Medical Center Research Institute, Inc Kansas City, Kansas, United States
  • Regents of the University of Michigan Ann Arbor, Michigan, United States
View all 14 locations
View Trial Details

Related conditions